Enanta Pharmaceuticals
ENTA
131 hedge funds and large institutions have $621M invested in Enanta Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 55 increasing their positions, 27 reducing their positions, and 19 closing their positions.
104% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 27
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
74% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 19
63% more capital invested
Capital invested by funds: $380M → $621M (+$241M)
12% more funds holding
Funds holding: 117 → 131 (+14)
11% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $1.39M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
+$14.5M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$11M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$10.3M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$9.32M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$9.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$12.1M |
| 3 |
Millennium Management
New York
|
-$8.17M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$4.72M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.55M |
ENTA Hedge Fund Activity: Q2 2015 in Review
131 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2015, worth a combined $621M — up 63% from $380M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ENTA positions and 19 closed out — a net gain of 14 holders — while 55 added to existing stakes and 27 trimmed.
The largest buyer was VOYA Investment Management, opening a new position worth an estimated $14.5M. The largest seller was Fidelity Investments, cutting an estimated $15.8M.
- 131 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2015, up from 117 in Q1 2015.
- Funds reported $621M of Enanta Pharmaceuticals stock for Q2 2015, up 63% quarter-over-quarter.
- 33 funds opened new Enanta Pharmaceuticals positions in Q2 2015 and 19 closed out, a net change of +14 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2015 was VOYA Investment Management, an estimated $14.5M added.
- The largest Enanta Pharmaceuticals seller in Q2 2015 was Fidelity Investments, an estimated $15.8M sold.
Based on aggregated 13F filings for Q2 2015.